Core Viewpoint - The company is focused on applying ultrasound and ray technology across various fields to meet diverse user needs, with a particular emphasis on ultrasound applications in the brain area, where it has achieved multiple patents and software copyrights [2]. Group 1 - The company has developed various models of ultrasound diagnostic products specifically for brain examinations [2]. - The application of ultrasound in the brain is a key area of research and development for the company [2]. - Detailed information regarding the company's patents and software copyrights can be found in its prospectus and periodic reports [2].

Group 1: Company Strategy and Focus Areas - The company aims to enhance its core competitiveness through industrial investments, focusing on the medical imaging and non-destructive testing sectors [2][3] - The company is actively seeking acquisition opportunities that align with its strategic development [2][3] - The company plans to expand its product portfolio through both depth and breadth, targeting cross-sector development [2][3] Group 2: Product Development and Market Position - The company has developed a portable multi-modal medical imaging system for emergency rescue applications, integrating portable DR and ultrasound devices [3][4] - The company’s industrial ultrasonic testing equipment is widely used in aerospace, petrochemicals, energy, and transportation sectors [4][5] - Key products include multi-modal medical imaging systems, specialized ultrasound diagnostic equipment, and automated non-destructive testing devices, which are expected to drive future revenue growth [5][6] Group 3: Research and Development - The company has participated in multiple national and provincial major research projects, with details disclosed in its prospectus and periodic reports [4][5] - The company has made advancements in AI-based breast cancer screening technology, enhancing the accuracy and efficiency of early detection [5][6] Group 4: Marketing and Sales Strategy - In 2025, the company will adjust its marketing strategy, focusing on major cities like Guangzhou, Shenzhen, Shanghai, and Beijing to strengthen its domestic and overseas marketing efforts [7][8] - The company aims to enhance its marketing network by attracting high-quality domestic and international distributors and improving local customer service capabilities [7][8] Group 5: Revenue Contribution - The sales revenue from surgical robots and automated non-destructive testing equipment constitutes a significant portion of the company's overall revenue [8]

证券代码：301602 证券简称：超研股份 公告编号：2025-045 汕头市超声仪器研究所股份有限公司 关于参加广东辖区上市公司 2025 年投资者网上集体接待日 活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，汕头市超声仪器研究所股份有限公司 （以下简称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"2025 年广东辖区投资者集体接待日暨辖区上市公司中报业绩说明会活动"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周 五）15:30-17:00。届时公司高级管理人员、独立董事将在线就公司 2025 年半年 度业绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟 通与交流，欢迎广大投资者踊跃参与！ 特此公告。 汕头市超声仪器研究所股份有限公司 董事会 2025 年 9 月 16 日 ...

Core Points - The company held its second extraordinary general meeting on September 15, 2025, where multiple important resolutions were reviewed and passed with high votes [1] - The meeting utilized a combination of on-site and online voting, with a total of 105 shareholders and representatives present, representing 364,475,192 shares, which is 85.0922% of the total voting shares [1] Summary of Resolutions - Amendment of the Articles of Association: Total votes in favor were 364,364,792 shares, accounting for 99.9697% [2] - Revision of the Shareholders' Meeting Rules: Total votes in favor were 364,363,692 shares, accounting for 99.9694% [3] - Revision of the Board Meeting Rules: Total votes in favor were 364,360,392 shares, accounting for 99.9685% [3] - Revision of the Independent Director Work System: Total votes in favor were 364,361,692 shares, accounting for 99.9689% [3] - Revision of the External Guarantee Management System: Total votes in favor were 364,357,992 shares, accounting for 99.9678% [3] - Revision of the Related Party Transaction Management System: Total votes in favor were 364,368,592 shares, accounting for 99.9708% [3] - Revision of the External Investment Management System: Total votes in favor were 364,358,392 shares, accounting for 99.9680% [3] - Revision of the Controlling Shareholder and Actual Controller Behavior Norms: Total votes in favor were 364,371,492 shares, accounting for 99.9715% [3] - Revision of the Code of Conduct for Directors and Senior Management: Total votes in favor were 364,362,992 shares, accounting for 99.9692% [3] - Revision of the Fund Usage Management System: Total votes in favor were 364,359,092 shares, accounting for 99.9681% [3] - Revision of the Major Transaction Management System: Total votes in favor were 364,367,292 shares, accounting for 99.9704% [3] Abolishment of Supervisory Committee Regulations - The resolution to abolish the Supervisory Committee Meeting Rules was passed with total votes in favor of 364,373,192 shares, accounting for 99.9720% [4]

国浩律师(广州)事务所 关于汕头市超声仪器研究所股份有限公司 2025 年第二次临时股东会的法律意见 汕头市超声仪器研究所股份有限公司: 根据中国证券监督管理委员会发布的《上市公司股东会规则》(以下简称《股 东会规则》）的要求,国浩律师(广州)事务所(以下简称"本所")接受汕头市超 声仪器研究所股份有限公司(以下简称"超研股份")的委托,指派周姗姗、林嘉 豪律师(以下简称"本所律师")出席超研股份 2025 年第二次临时股东会(以下简 称"本次股东会")，对本次股东会的召集与召开程序、出席会议人员与召集人 的资格、表决程序与表决结果等重要事项出具法律意见。 本所及本所律师依据《中华人民共和国公司法》(以下简称《公司法》)、《律 师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规则(试 行)》等规定及本法律意见书出具日以前已经发生或者存在的事实,严格履行了 法定职责,遵循了勤勉尽责和诚实信用原则,进行了充分的核查验证,保证本法 律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不 存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 一、本次股东会的召集与召开 律师(广州 ...

证券代码：301602 证券简称：超研股份 公告编号：2025-044 汕头市超声仪器研究所股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、会议召开时间： （1）现场会议：2025年9月15日（星期一）15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为2025 年9月15日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为2025年9月15日9:15-15:00期间的任意时间。 2、现场会议召开地点：广东省汕头市金砂路77号汕头市超声仪器研究所股 份有限公司1楼会议室。 3、召开方式：本次股东会采取现场投票与网络投票相结合的表决方式。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一） 召开情况 4、召集人：汕头市超声仪器研究所股份有限公司董事会 5、主持人：董事长李德来先生 6、会议的召开符合相关法律、行政法规、部门规章、规范性文件和公司 ...

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant focus on the pet economy and smart medical technology [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%. The net profit attributable to the parent company was 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% [8]. Market Position and Trends - The company participated in the 97th WVC annual meeting, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2]. - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [2]. Stock Performance - On September 9, the company's stock price fell by 1.93%, with a trading volume of 71.26 million yuan and a turnover rate of 4.80%, resulting in a total market capitalization of 10.871 billion yuan [1].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is experiencing growth in the pet economy and smart medical sectors, benefiting from the depreciation of the RMB and being a newly listed stock under the registration system [2]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [3][7]. - The company was established on November 15, 1982, and was listed on January 22, 2025 [3][7]. - The main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, with an average of 2,456 circulating shares per person, an increase of 19.98% [8]. Market Position and Trends - The company participated in the 97th WVC annual conference, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and engaging with industry experts [2]. - The company’s overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [2]. Shareholder Composition - As of June 30, 2025, the largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.9127 million shares, followed by Southern Zhongzheng 1000 ETF with 514,500 shares [9].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant focus on the pet economy and smart medical technology [2][3][7]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the first half of 2025, the company achieved a revenue of 184 million yuan, representing a year-on-year growth of 15.00%. The net profit attributable to the parent company was 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% [8]. Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. - The company is involved in various concept sectors, including nuclear power, medical devices, smart healthcare, and newly listed stocks [7]. Recent Developments - The company participated in the 97th WVC Annual Conference from March 3 to 5, 2025, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices, enabling remote image transmission and online diagnostic guidance through its "Mali Doctor" platform [2][3]. Stock Performance - On September 4, 2025, the company's stock price fell by 1.18%, with a trading volume of 84.1682 million yuan and a turnover rate of 5.71%, resulting in a total market capitalization of 10.738 billion yuan [1]. - The average trading cost of the stock is 27.20 yuan, with the current price approaching a resistance level of 25.49 yuan, indicating potential for upward movement if this level is breached [6].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Group 1: Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. - The company has a significant overseas revenue share of 55.26%, benefiting from the depreciation of the RMB [3]. Group 2: Financial Performance - For the period from January to June 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, a year-on-year increase of 18.50% [8]. - The company has distributed a total of 43.69 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On September 1, the company's stock rose by 0.69%, with a trading volume of 95.83 million yuan and a turnover rate of 6.26%, resulting in a total market capitalization of 11.27 billion yuan [1]. - The stock has seen a net outflow of 205,000 yuan from major funds today, with a continuous reduction in major fund holdings over the past three days [4][5].